secwatch / observer
FBRX Forte Biosciences, Inc.
CIK 0001419041 23 ready 8-Ks latest May 14, 2026, 4:42 PM ET RSS · JSON
Activity: NORMAL 2 filings / 30d vs 1 baseline
Ready 8-Ks 23
Latest filing June 2, 2026, 4:01 PM ET
Top materiality 0.85
Event mix other_material ×11 · earnings ×9 · other ×2
Sentiment 4 pos · 0 neg · 19 neu
Latest earnings reported 2026-Q1
Executive change recent →

Recent 8-K filings for FBRX

Highest-materiality recent filing

Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April

May 14, 2026, 4:42 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

Read filing →

Executive changes

Departed

Lawrence Eichenfield

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Appointed

Richard Vincent

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Departed

Donald A. Williams

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.
Appointed

Shiv Kapoor

Director
FBRX · Forte Biosciences, Inc.
Effective
2024-09-17
Filed
September 20, 2024, 7:59 PM ET
On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.

Earnings & guidance

2026-Q1 EPS reported -$1.24 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

4 positive 0 negative 19 neutral

source · FBRX on sec.gov